Moreover, appropriate management definition in this study did not take into account intermediate cases of luminal breast cancer where the choice between chemotherapy followed by endocrine therapy versus endocrine therapy alone is based on genomic signatures or at least a proliferative index like Ki67. The gene discussed is MKI67; the disease is breast carcinoma.